LBI-HTA - Publications - Search - Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018. HSO: 36th Prioritisation.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

For the 36th prioritisation (May 2018), 12 drugs were filtered out of 404 identified and were sent to prioritisation. Of these, 7 drugs were ranked as 'highly relevant' by the expert panel, 5 as 'relevant' and none as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Series Name:HSO: 36th Prioritisation
Deposited on:12 Jun 2018 12:34
Last Modified:12 Jun 2018 12:34

Repository Staff Only: item control page